Pluspunten
Decent pay Conveniently located office
Minpunten
It’s disappointing to say this, but the company that Formation Bio used to be feels very far away now. A few years back it operated like a genuinely strong tech organization—well-run, community-oriented, with clear direction and several thoughtfully developed products underway. Over the past two years, though, things have shifted in ways that have been hard to watch. The transition toward an AI-centric strategy splintered teams and created constant reshuffling. Projects representing years of engineering effort were abruptly shelved, often because they hadn’t been thoroughly validated from the start. Many of the strongest engineers moved on, and a lot of the culture left with them. Those still there often appear drained, worn down by nonstop reorganizations and shifting priorities. The most significant change has been the move away from impactful work on improving clinical trial efficiency toward a model centered on acquiring and reselling assets. As the tech-driven identity of the company faded, the environment began to resemble more of a finance-oriented culture, along with the personality types that usually come with that shift.